Prognostic value of immunohistochemical marker HER2/neu in patients resected for gastric cancer stage IIIA
DOI:
https://doi.org/10.14739/2310-1210.2014.2.25417Keywords:
gastric cancer, immunohistochemical biomarker HER2/neu, overall survivalAbstract
Introduction
Patients with the same stage of malignancy often have different life-span, which makes it necessary to search for new prognostic factors.
The high incidence and low survival rate of patients with gastric cancer also cause an increased interest in studying the immunohistochemical profile of tumors of the stomach. Recently, researchers are studying the prognostic significance of immunohistochemical markers such as: EGFR [10], VEGF [12,15,18], HER2/neu [8,17,19], expression of betakatenin [1], hERG1 [7], p53 [14], PCNA [14,20]
Of particular interest is the HER2/neu. Overexpression of HER2/neu promotes tumor growth and plays an important role in the pathogenesis of some human malignancies [17].Nevertheless, the impact of HER2/neu status on the prognosis of patients with gastric cancer remains controversial [6,11,19]. Nakajima Garcia and colleagues believe that the increased expression of HER2/neu in patients with gastric cancer correlates with poor prognosis and more aggressive disease [11]. At the same time, Begnami found that life expectancy in gastric cancer patients with HER-2/neu-positively stained tumors was significantly shorter than in patients with HER-2/neu-negatively stained tumors (17 months vs. 40 months, respectively, p=0.023) [5].
The aim of research
Study the prognostic significance of immunohistochemical marker HER-2/neu in patients resected for gastric cancer stage IIIA.
Materials and methods
Materials for the study were histologic surgical specimens of the primary tumor in 21 patients who had surgery in the Zaporozhye Regional Clinical Oncology Center due to stomach cancer stage IIIA, including 14 men (67%) and 7 females (33%).
Patients underwent surgery in the volume: gastrectomy and distal subtotal resection, 86% of patients received adjuvant chemotherapy of standard schemes.
Immunohistochemical study of HER2/neu (erbB-2) used a rabbit polyclonal antibody. Immunohistochemical reaction was evaluated as negative in the absence of expression of membrane receptors or HER2/neu coloring immunopositive less than 5% of tumor cells ("-" - no reaction) as low positive - in the presence of 6-10 % of tumor cells immunopositive ("+"), moderately positive - 10-50% ("++") and high pozitive - 50% positive tumor cells ("+++"). For further comparative immunohistochemical study identified two main levels of immunoreactivity: low or reduced protein expression (-/+) and high level or overexpression of the marker (++/+++).
To assess survival used the Kaplan - Meier. Comparison of survival curves was performed using the Cox-F test.
Results
The largest group of patients with gastric cancer stage IIIA consisted of patients with a negative reaction to the presence of receptor HER2/neu (47,6%), the second place is a group of patients with moderately positive reaction - 23.8%, patients with low positive and high pozitive reactions were equally divided - by 14.3%.
Median survival of patients with gastric cancer stage IIIA was 19.8 months.
The study two groups of patients with a low level or reduced protein expression (-/+) and high level or overexpression of the marker (++/+++) showed a higher survival rate in the former group (median survival was 50 months) compared to the second group, where the median was equal to 16 months (p<0.05).
Conclusion
1. Median survival of patients with gastric cancer operated stage IIIA was on average 19.8 months.
2. High level or overexpression of marker HER2/neu (++/+++) is bad prognostic sign for life expectancy of patients with stage IIIA (p<0.05).
3. The prospect of further study is research of the prognostic value of marker HER2/neu in patients with gastric cancer stages I and II.
References
Zenyukova T.V., Zenyukov A.S. Meaning of the expression E-cadherin and β-catenin in gastric cancer. Siberian Journal of Oncology 2011; application number 1: 55.
Sabirov A.H. Histological, immunohistochemical and molecular genetic markers for breast cancer and their prognostic significance: Author. dis. for a researcher. Ph.D degree of Medicine: special. 03.03.04 "Cell biology, cytology, histology". Tyumen, 2010. 20 p.
Samofalova O. Y. Immunohistochemical markers as a prognostic factor in the surgical treatment of colorectal cancer: Author. dis. for a researcher. degree of Medicine: special. 14.01.17 "Surgery", 14.00.15 "Pathological Anatomy". Moscow, 2012. 24 p.
Frank G.A. Morphology of prostate cancer. Practical Oncology 2008, 9 (2): 65-70.
Barros-Silva J. D., Leitão D., Afonso L. et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients . Br. J. Cancer 2009; 100(3): 487-493.
Begnami M. D., Fukuda E., Fregnani J. H. et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinoma: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011, 22: 3030-3036.
Ding X. W., Yang W. B., Gao S. et al. Prognostic significance of hERG1 expression in gastric cancer. Digestive Diseases and Sciences 2010; 55(4): 1004–1010.
Fornaro L., Lucchesi M., Caparello C. et al. Anti-HER agents in gastric cancer: from bench to bedside. Nature Reviews Gastroenterology and Hepatology 2011; 8(7): 369–383.
Frogne T., Benjaminsen R. V., Sonne-Hansen K. et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment 2009; 114(2): 263–275.
Gamboa-Dominguez A., Dominguez-Fonseca C., Quintanilla-Martinez L. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Modern Pathology 2004; 17(5): 579–587.
Gravalos C., Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008; 19(9): 1523-1529.
Iordache S., Saftoiu A., Georgescu C. V. et al. Vascular endothelial growth factor expression and microvessel density—two useful tools for the assessment of prognosis and survival in gastric cancer patients. Journal of Gastrointestinal and Liver Diseases 2010; 19(2): 135–139.
Lastraioli E., Bencini L., Bianchini E. et al. hERG1 channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: a pilot study. Translational Oncology 2012; 5(2): 105–112.
Lee Kyu Eun, Lee Hyuk-Joon, Kim Yoon Ho et al. Prognostic Significance of p53, nm23, PCNA and c-erbB-2 in Gastric Cancer. Jpn. J. Clin. Oncol. 2003; 33(4): 173-179.
Maeda K., Kang S.-M., Onoda N. et al. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer. 1999; 86(4): 566–571.
Moasser M. M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis . Oncogene 2007; 26(45): 6469-6487.
Park D., Yun J. Won, Park J. Ho et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51(8): 1371–1379.
Schimanski C. C., Schlaegel F., Jordan M. et al. VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World Journal of Surgery 2011; 35(5): 1010–1016.
Tanner M. et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005; 16(2): 273–278.
Zafirellis K., Karameris A., Milingos N. Molecular Markers in Gastric Cancer: Can p53 and Bcl-2 Protein Expressions be Used as Prognostic Factors? Anticancer Res. 2005; 25(5): 3629-3636.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
